Diasmoke 2.0Diasmoke 2.0 assess the short and long term reduction of cardio-respiratory risk, correlated to the use of combustion-free products, in diabetic patients.
The marketing of the electronic cigarette (EC) and its worldwide spread as a competitor of existing therapies has presented new opportunities for the control and prevention of tobacco. Therefore, it is hypothesized that an integrated smoking cessation program (brief counseling + EC with nicotine) in diabetic smokers may have similar smoking cessation rates to those obtained using standard approaches. A 12-week randomized controlled clinical trial and a 24-month follow-up to monitor changes in clinical and instrumental parameters in a target population of 900 diabetic smokers (300 for each center) divided into two different smoking cessation programs: group A (new approach) short term + EC with nicotine; group B (approved standard approach) short consultancy. The main objectives are: to evaluate the effectiveness of the new smoking cessation treatment; evaluating the safety of the new treatment in diabetic smokers; assess health effects in the short and long term.